Board of Directors

   
Dawn Svoronos
Chair of the Board
Ms. Dawn Svoronos (formerly Graham) worked in the commercial side of the business for the multinational pharmaceutical company Merck & Co. Inc., for 23 years, retiring in 2011. From 2009 to 2011, Ms. Svoronos was President of the Europe/Canada region for Merck and from 2006 to 2009 was President of Merck in Canada. Previously held positions with Merck include Vice President of Asia Pacific and Vice President of Global Marketing for the Arthritis, Analgesics and Osteoporosis franchise. Ms. Svoronos sits on the Boards of Directors of PTC Therapeutics in New Jersey and Xenon Pharmaceuticals Inc. in Burnaby, British Columbia.
   
Gérald A. Lacoste, Q.C.
Corporate Director
Gérald Lacoste is a lawyer with extensive experience in the fields of securities regulation, corporate finance and corporate governance. He was previously Chairman of the Quebec Securities Commission (now known as the Autorité des marchés financiers) and was also President and CEO of the Montreal Stock Exchange. Mr. Lacoste is a member of the North American Free Trade Agreement (NAFTA) arbitration panel.
   
David D. Lilley
Corporate Director
David D. Lilley has been actively involved in a number of different roles in the pharmaceutical industry on a worldwide basis. He has worked in both the pharma and services sectors of the industry and has been involved in both the development and commercialization of prescription medicines. He has been acting as managing partner of Pleasanton Pharma Ventures since 2014. From 2008 to 2010, he was executive vice president of Campbell Alliance where he created and oversaw strategic relationships with clients new to the firm. Prior to that, he spent 12 years (1996-2008) at Quintiles International where he held various executive positions. During his tenure at Quintiles, he was initially responsible for leading the global marketing and business development. He later was appointed to be global president of Innovex UK Ltd., the contract sales and marketing division of the company. He also oversaw a number of strategic acquisitions with a focus on new services or geographic expansion. David holds a degree in Medicinal Chemistry from the University of London.
   
Paul Pommier, MBA
Corporate Director
Paul Pommier spent over 25 years at National Bank Financial, his last position being Senior Executive Vice President, Corporate and Government Finance. Throughout his career, he oversaw public and private financings, mergers and acquisitions, as well as the marketing of investment offerings. Retired since 1997, Mr. Pommier acted as Chairman of the Board of Theratechnologies between 2007 and 2013.
   
Jean-Denis Talon
Corporate Director
Jean-Denis Talon had a successful career with AXA Insurance over a period of more than 20 years ultimately becoming President and Chief Executive Officer. Mr. Talon is the former Chairman of the Board of AXA Canada and is also a former President of the Financial Affairs Committee at the Insurance Bureau of Canada.
   
Luc Tanguay, M.Sc., CFA
President and Chief Executive Officer
Luc Tanguay has been active in the biotechnology industry for over 20 years. As a member of senior management at Theratechnologies since 1996, he has contributed to the Company’s growth by facilitating access to public and private capital funding. A member of the Board of Directors since 1993, he has held various management posts since joining the Company. Prior to joining Theratechnologies, Mr. Tanguay had a successful career in investment banking at Lévesque Beaubien (now National Bank Financial) where he helped several organizations establish themselves as public companies.